{"id":9997,"date":"2026-10-30T16:50:10","date_gmt":"2026-10-30T11:20:10","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-30\/"},"modified":"2026-10-30T16:50:12","modified_gmt":"2026-10-30T11:20:12","slug":"maxhealth-share-price-today-2026-10-30","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-30\/","title":{"rendered":"Max Healthcare Ins Share Price Today: Why MAXHEALTH Is Rising 1.04% | 30 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: MAXHEALTH<\/strong> \u00b7 30 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b9860.00<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+1.04%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b9882.85 \/ \u20b9849.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b9851.15<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>68.56 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>30 October 2026 \u00b7 03:25 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Max Healthcare Institute Limited shares moved higher in Thursday&#x27;s trading session, closing up 1.04% at \u20b9860.00 compared to its previous close of \u20b9851.15.<\/li>\n<li>allotment of Equity Shares under Max Healthcare Institute Limited &#8211; Employee Stock Option Scheme 2022<\/li>\n<li>Trading volume was 1.70 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Max Healthcare Ins share price rising on 30 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Max Healthcare Institute Limited shares moved higher in Thursday&#x27;s trading session, closing up 1.04% at \u20b9860.00 compared to its previous close of \u20b9851.15.<\/p>\n<p class=\"wt-copy\">The broader market and sectoral backdrop remained positive, with the benchmark Nifty rising 0.51% and the Nifty Pharma sector index advancing 1.55%. Max Healthcare&#x27;s gain reflects steady sector participation, outperforming the broader Nifty index while trading alongside broader momentum in healthcare equities.<\/p>\n<p class=\"wt-copy\">The price movement coincided with the company&#x27;s release of its financial results for the quarter and half year ended September 30, 2026, alongside board approvals for significant brownfield expansions. While these fundamental disclosures provide context for ongoing business performance, the day&#x27;s market move reflects a combination of sector tailwinds and active cash-market participation.<\/p>\n<p class=\"wt-copy\">68.56 lakh shares traded by 30 October 2026 \u00b7 03:25 PM IST. This compares with a 20-day average daily volume of 40.38 lakh shares (1.70 times). The five-day average daily volume was 44.81 lakh shares. Separately, the NSE report for 29 October 2026 showed 35.02 lakh shares delivered, representing 71.00% of that day\u2019s traded volume. The same report recorded 104,050 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Earnings release context and sector-aligned participation<\/strong><\/p>\n<p class=\"wt-copy\">The stock&#x27;s upward movement of 1.04% aligns with positive sector momentum and heightened cash volume alongside the release of quarterly financial results and capacity expansion announcements.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Allotment of Securities<\/div>\n<div class=\"wt-card-date\">30 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">allotment of Equity Shares under Max Healthcare Institute Limited &#8211; Employee Stock Option Scheme 2022<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026110106_SE_Intimation_Allotment_of_Equity_Shares.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">ESOP\/ESOS\/ESPS<\/div>\n<div class=\"wt-card-date\">30 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">grant of options under Max Healthcare Institute Limited &#8211; Employee Stock Option Scheme 2022<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026105713_SE_Intimation_Grant_of_ESOPs.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">23.71%<\/div>\n<div class=\"wt-note\">23.71% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">40.52%<\/div>\n<div class=\"wt-note\">41.78% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">71.52%<\/div>\n<div class=\"wt-note\">71.74% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1740060_16102026044443_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 19.25% on 30 September 2026. This compares with 18.68% on 30 June 2026, a change of +0.57 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 40 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Hdfc Mutual Fund through various schemes<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">3.17 crore shares \u00b7 3.26%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Invesco Mutual Fund through various schemes<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.79 crore shares \u00b7 2.87%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI Mutual Fund through various schemes<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.52 crore shares \u00b7 2.59%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1740060_16102026044443_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution progress on the approved \u20b9415 crore brownfield bed capacity expansions at Noida, Vaishali, and BLK Max<\/li>\n<li>Ramp-up and occupancy trends at the newly commissioned Oncology Block at MSSH Dwarka<\/li>\n<li>Cash volume and delivery percentage trends relative to the 20-day average volume of 1.70x<\/li>\n<li>Progress on the Gurugram Sector-56 hospital project targeting completion by April 2027<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-21\/\">Max Healthcare Ins Share Price Today: Why MAXHEALTH Is Falling 0.43% | 21 October 2026 \u2014 21 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-13\/\">Max Healthcare Ins Share Price Today: Why MAXHEALTH Is Falling 2.81% | 13 October 2026 \u2014 13 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-06\/\">Why MAXHEALTH Shares Fell 1.58% Today: Sector Divergence Explored | 6 October 2026 \u2014 6 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/maxhealth\/\">More Max Healthcare Ins news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Max Healthcare Ins company news?<\/h3>\n<p class=\"wt-copy\">allotment of Equity Shares under Max Healthcare Institute Limited &#8211; Employee Stock Option Scheme 2022<\/p>\n<h3>How strong was Max Healthcare Ins\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">68.56 lakh shares traded, 1.70 times the 20-day average daily volume. The price and volume data are dated 30 October 2026 \u00b7 03:25 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-30\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/maxhealth-share-price-today-2026-10-30\/\"}, \"headline\": \"Max Healthcare Ins Share Price Today: Why MAXHEALTH Is Rising 1.04% | 30 October 2026\", \"description\": \"Max Healthcare Ins share price rose 1.04% to \u20b9860.00 today. See why MAXHEALTH is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-30T16:50:00.048886+05:30\", \"dateModified\": \"2026-10-30T16:50:00.048886+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Max Healthcare Ins\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"MAXHEALTH\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/maxhealth-company-news-2026-10-30.jpg\"]}]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"General Updates\",\"summary\":\"Presentation on Earnings Update for the quarter and half year ended September 30, 2026\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 14:57:07\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026145653_PR_EU_Vf.pdf\",\"disclosure_text\":\"\"},{\"title\":\"Change in Management\",\"summary\":\"appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs, identified as Senior Management Personnel with effect from November 1, 2026\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 14:54:35\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026145418_Outcome_BM.pdf\",\"disclosure_text\":\"October 30, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MAXHEALTH Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543220 Sub.: Outcome of Board Meeting Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir \/ Madam, In continuation to our earlier intimation dated October 23, 2026, we wish to inform that the board of directors (\u201cBoard\u201d) of the Company at their meeting held today i.e. October 30, 2026, inter-alia, transacted following businesses: Financial Results Approved the unaudited standalone & consolidated financial results (\u201cFinancial Results\u201d) of the Company for the quarter and half year ended September 30, 2026, based on the recommendation of Audit Committee. Financial Results together with unmodified limited review reports issued by M\/s. S.R. Batliboi & Co. LLP, Chartered Accountants, Statutory Auditors of the Company are enclosed as Annexure - I. Capital expenditure for expansion of Max Super Speciality Hospital, Sector-128, Noida Approved capital expenditure of ~\u20b993 Crore towards the redevelopment and clinical capacity enhancement programme at Max Super Speciality Hospital, Sector -128, Noida (\u201cMSSH Noida\u201d). MSSH Noida is run and operated by Crosslay Remedies Limited (formerly known as \u2018Jaypee Healthcare Limited\u2019) , a wholly -owned subsidiary of the Company (\u201cCrosslay\u201d). Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201c SEBI Listing Regulations\u201d) are enclosed as Annexure - II. Capital expenditure for expansion of Max Super Speciality Hospital, Vaishali Approved capital expenditure of ~\u20b997 Crore towards the construction of additional floors at over the existing tower at Max Super Speciality Hospital, Vaishali (\u201cMSSH Vaishali\u201d). MSSH Vaishali is run and operated by Crosslay. Details as required under the SEBI Listing Regulations are enclosed as Annexure - III. Appointment of Senior Management Personnel Approved the appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs , identified as Senior Management Personnel with effect from November 1, 2026 , based on the recommendation of Nomination and Remuneration Committee. Details as required under the SEBI Listing Regulations are enclosed as Annexure - IV. Update on Construction of ~525 bedded hospital at Sector - 56, Gurugram In continuation of our earlier intimation dated May 22, 2024, approved the revision of the project cost to ~\u20b91,143 Crore and the timeline for completion of the proposed ~525 bedded hospital at Sector - 56, Gurugram to April 2027. The revision in project cost is primarily attributable to changes in fa\u00e7ade specifications, additional construction requirements, development of the atrium and enhanced interior fit -outs. All other aspects of the project, other than the revised project cost and completion timeline, remain unchanged. The Board meeting commenced at 12.50 pm (IST) and concluded at 2.35 pm (IST). This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above S.R. BArL1B01 & Co. LLP Chartered Accountants 67. Institutional Area Sector 44, Gurugram - 122 003 Haryana, India Tel : +91 124 681 6000 Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Max Healthcare Institute Limited 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Resu lts of Max Healthcare Institute Limited {the \\\"Holding Company\\\") , its subsidiarie s and its deemed separate ent ities, that is 'Silos' over which the Holding Company has control (the Holding Company , its subsidiarie s and its deemed separate entities that is 'Si los\\\", together referred to as \\\"the Group \\\") for the quarter ended September 30, 2026 and year to date from April I, 2026 to September 30, 2026 (the \\\" Statement\\\") attached herewith , being submitted by the Holding Company pursua nt to the requirement s of Regu lation 33 of the SEB I (L isting Obligat ions and Disclosure Requirements) Regulations , 20 15, as amended (the \\\"List ing Regulations \\\"). 2. The Holding Compan y's Management is responsib le for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Account ing Standard 34, (Ind AS 34) \\\"Interim Financial Reporting \\\" prescribed under Sect ion 133 of the Companies Act, 2013 as amended , read with relevant rules issued thereunder and other accou nting principles genera lly accepted in India and in compliance with Regulation 33 of the Listing Regulation s. The Statement has been approved by the Holdin g Company's Board of Direct ors. Our responsibi lity is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 24 10, \\\"Review of Interim Financial Information Performed by the Independent Auditor of the Entity \\\" issued by the Institute of Chartered Accountants of India. This standa rd requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of materia l misstatement. A review of interim financial information cons ists of making inquiries , primar ily of persons respons ible for financial and accou nting matters , and app lying analytical and other review procedures. A review is substantia lly less in scope than an audit conducted in accorda nce with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly , we do not express an audit opin ion. We also performed procedure s in accordance with the Circular No. CIR\/CFD \/CMD 1\/44\/20 19 dated March 29, 20 19, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regu lations, to the extent applicable. 4. The Statement includes the resu lts of the following entit ies as mentioned in Annexure I. 5. Based on our review conducted and procedures performed as stated in paragrap h 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompany ing Statement , prepared in accordance with recognition and measurement principles laid down in the aforesa id Indian Account ing Standards ('Ind AS') specifie d under Section 133 of the Comp;mies Act, 2013 , as amended , read with relevant rules issued thereunder and other accounting principles generally accepted in India , has not disclosed the informat ion required to be disclosed in terms of the Listing Regulations , including the manner in which it is to be disclosed , or that it contains any material misstate ment. 6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of four subsidiaries , whose unaudited interim financial results include total assets of Rs. 33,690 Lakhs as on September 30, 2026, tota l revenues of Rs. 3,666 Lakhs and Rs. 5,547 Lakhs , total net profit after tax of Rs. 20 Lakhs and Rs. 81 Lakhs, total comp rehensive incom e of Rs. 5 Lakhs and Rs. 68 Lakhs , for the quarter ended September 30, 2026 , and the period ended on that date respectively , and net cash inflow of Rs. 8,777 Lakhs for the period from Apr il O I, 2026 , to September 30, 2026, as considered in the Statement which have been reviewed by their respective indepe ndent auditors. S.R. Batlibol g Co LLP, a Limited Llablllty Partnership with LLP Identity No. AAB\u20224 294 Rcgd Office\u00b7 22. Cam,,c S1n:-c1. Block \u00b7e\u00b7. Jrd Floor. Kolk.11a-700 016 S.R. BArL1B01 & Co. LLP Chartered Accountants The independent auditor ' s reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Stateme nt, in so far as it relates to the amount s and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedure s perfo rmed by us as stated in paragraph 3 above. 7. The accompany ing Statement include s unaud ited interim financ ial results and other unaudit ed financia l information in respect of two subsidiarie s, whose interim financia l results and other financial inform ation reflect total assets of Rs. 936 Lakh s as on September 30, 2026 , total revenues of Rs. nil and Rs. nil, total net (loss) after tax of Rs. (532) Lakh s and Rs. (862) Lakhs, total comprehensive (loss) of Rs. (533) Lakhs and Rs. (864) Lakh s, for the quarter ended Septemb er 30, 2026 , and period ended on that date respectively , and net cash outflo ws of Rs. ( 140) Lakhs for the period from April 01 , 2026 , to Sept ember 30, 2026. The unaudited interim financial results and other unaudit ed financ ial inform ation of these subsidiaries have not been rev iewed by thei r auditor(s) and hav e been approved and furnished to us by the Management and our conclusion on the Statement , in so far as it relate s to the affair s of these subsidiar ies, is based solely on such unaudited interim financia l results and other unaudited financial informat ion. Accordin g to the information and explanations given to us by the Man agement , these inter im financia l resu lts are not materia l to the Group . Our conc lusion on the Statement in respect of matt ers stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the finan cial results certified by the Management. For S.R. Batliboi & Co. LLP Chartered Accountants ICAI Finn regi stration numb er: 30 I 003E\/E3 0000 5 \u00bd:cl\\u002d\\u002d per San jay Vij Partner Memb ership No.: 095 169 UDIN: l-1, 0'15 \\\\1,q Wy\\\\\/0 L-Jq511 Place : New Delhi Date: October 30, 2026 S.R. BATLIBOI & Co. LLP Chartered Accountants Annexure 1 to our report dated October 30, 2026, on the consol idated financia l results of Max Healt hcare Institute Limited for the qua rter ended September 30, 2026, and year to date from April 01, 2026 to Septem ber 30, 2026 List of subsidiaries \/ step down subsidia ries\/ silos S. No. Com pany Name Relationship 1 ALPS Hospital Limited (Formerly known as Max Hospitals Subs idiary Company and Allied Services Limited) 2 Hometrail Buildtech Private Limited Subsidiary Company 3 Crosslay Remedies Limited (Formerl y known as Jaypee Subsidiary Company Healthcare Limited) 4 Max Lab Limited Subsidiary Company 5 Eqova Healthc are Private Limited Subsidiary Company 6 Alexis Multi Specia lity Private Limited Subs idiary Company 7 Starl it Medical Centre Private Limited Step-down Subsidiary Company 8 Max Healthc are FZ LLC Subsidiary Company 9 MHC Global Healthcare (N igeria) Limited (Liquidat ed w.e.f. Subsidiary Company October 28, 2026) 10 Max Healthcare Foundatio n Subsidiary Company I I Kalinga Hospita l Limited (w.e .f. May 18, 2026) Subsidiary Company 12 Yerawada Propertie s Private Limited (w.e.f. June 30, 2026) Subsid iary Company 13 Operations of Dr. B.L. Kapur Memorial Hospital (A unit of Silo Lahore Hospital Society) 14 Operation s of Dr. Balabhai Nanavati Hospital (A unit of Silo Balabhai Nanavat i Hospital) 15 Operation s of Max Super Speciali ty Hospital, Dwarka (A unit Silo of Muthoot Hospitals Private Lim ited) SI. No. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. MAX HEALTHCARE INSTITUTE LIMITED CIN : L72200M H2001PLC322854 REGISTERED OFFICE: 401, 4th Floor , Man Excellenza, S. V. Road , Vile Parle (West), Mumbai-400056, Maharashtra Website : www.maxhealthcare.in . Email : investors@maxhealthcare .com. Phone : +91- 22 2610 0461 \/62 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2026 fin t lakhs excent ner eauitv share data) Pani culars Quarter ended September 30, June 30, 2026 2026 Unaudited Unaudit ed Income Revenue from operations 2.56.921 2.36.617 Other income 4.090 4,052 Total Income 2,61,011 2.40.669 Expenses Purchase of drugs. consumables and implants 52.194 52.116 Change in inventories of drugs. consumables and implants (663) (778) Employee benefits expense 39.931 38.818 Professional and consultancy fee 56.413 52.343 Finance costs 7.384 7.100 Depreciation and amortization expense 13.763 13.166 Other expenses 37.897 34.273 Total expenses 2,06,919 1 97,038 Profit before exceptional items and tax for the period\/yea r (1-2) 54,092 43,631 Exceptiona l items (refer note 5) Profit before tax for the oeriod\/vear 13-41 54,092 43,631 Tax expense (refer note 10) Current tax 9.531 8,246 Deferred tax charge\/(credit) 3,116 3.089 Total tax expense 12,647 11,335 Profit for the oeriod\/vear 15-61 41.445 32,296 Other comprehensive income Items that will not be reclassified to profit or loss Remeasurement of defined benefit plans 35 8 Income tax effect on above (6) (6) ltoms that will bo reclassified to profit or loss Fair value changes on derivalives designated as cash flow hedge 1.018 (644) Income tax effect on above (256) 162 Exchange differences on translation of foreign operation (1) (1) Other comprehensive income\/floss I 790 (481 Total comprehensive income for the oeriod\/vea r 17+8\\\\ 42.235 31,815 Profit\/(l oss) attribu table to: 41,445 32,296 Owners of the company 41.494 32.249 Non-controlling interests (49) 47 Other Comp rehensive income\/(loss) attribu table to: 790 (481) Owners of the company 796 (482) Non\u2022controlling interests (6) 1 Total Comprehensive incomef(loss) attributab le to: 42,235 31,815 Owners of the company 42.290 31.767 Non-controlling interests (55) 48 Paid-up equity share capita l 97,331 97,324 (Face value oft 10 per share) Reserves (other equity) Earnings per equity share (EPS) Not annualised Not annualised Basic-m 4.26 3.32 Diluted - (t) 4.24 3.30 Consolidated September 30, 2025 Unaudi ted 2.13.547 3.290 216,837 46.515 (26) 33.832 45.273 5,392 10.810 30.438 1 72,234 44,603 44,603 1.029 (5.556) 14,5271 49. 130 20 (1) (15) 4 49,134 49,130 49.130 4 4 49.134 49.134 97,224 Not annualised 5.05 5.02 Half-year ended September 30, September 30, 2026 2025 Unaudited Unaudited 4.93.538 4.16.304 8.142 6.941 5,01 680 423,245 1.04.310 91.897 (1.441) (884) 78.749 67.639 1.08.756 87.912 14.484 10.877 26.929 21.224 72.170 59.934 4,03,957 338,599 97,723 84,646 97 723 84.646 17.777 10.673 6.205 (5.954) 23.982 4,719 73 741 79,927 43 (326) (12) 65 374 (94) (2) (16) 309 1277 74,050 79.650 73,741 79,927 73.743 79.927 (2) 309 (277) 314 (277) (5) 74,050 79,650 74.057 79.650 (7) 97,331 97,224 Not annualised Not annualised 7.58 8.22 7.54 8.17 S.R. Ballibol & Co.i LP, for Identification~ Year ended March 31, 2026 Audited 8,37.345 16.262 8,53,607 1.79.875 (873) 1.35.712 1.79.401 23.510 44.653 1.18.947 6,81,225 1,72,382 4,824 1 67,558 21.131 2.186 23,317 1,44.241 (181) (3) 26 (158 1.44.083 1,44.241 1.44.241 (158) (158) - 1,44,083 1.44.083 97,313 9,77,350 Annualised 14.83 14.76 MAX HEALTHCARE INSTITUTE LIMITED CIN : L72200MH2001 PLC322854 REGISTERED OFFICE : 401, 4th Floor, Man Excellenza , S. V. Road, Vile Parle (West) , Mumbai-400056 , Maharashtra Website: www.m axhealthcare.in. Email: investors@maxhea lthcare.com. Phone: +91-22 2610 0461\/62 UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026 As at Part icul ars September 30, 2026 Unaudited ASSETS Non-current assets: Property, plant and equipment 6.05,366 Right-of-use assets 1.71,011 Capital worl<-in-prngress 80,451 Investment property 466 Goodwill 3,68,920 Other intangible assets 2,49,928 Intangible assets under developme nt 945 Financial assets ( i) Investments 546 (ii) Trade receivables 7,348 (iii) Loans 83.996 (iv) Other financial assets 23,315 Income tax assets (net) 31,522 Deferred tax assels 3,198 Other non-current assets 35,574 Total non.current assets 16,62,586 Current assets : Inventories 13,181 Financial assets (i) Trade receivables 1,24,336 (ii) Cash and cash equivalents 55.671 (iii) Bank balances other than (ii) above 1,425 (iv) Loans 987 (v) Other financial assets 6,988 Income lax assets (net) 451 Other current assets 6.587 Total current assets 2,09,626 TOTAL ASSETS 18,72,212 EQUITY AND LIABILITIES EQUITY Equijy share capital 97,331 Other equity 10,35,872 Equity attributable to owners of the Compa ny 11,33,203 Non-controlling interests 20,110 Total equity 11,53,313 LIABILITIES Non-current llabiliti es: Financial liabiltties (i) Borrowings 2,62,098 (ii) Lease liabilities 54,997 (iii) Other financial liabilities 32,277 Provisions 13.916 Deferred tax liabilities 82.585 Other non\\u002d\\u002dcurrent liabihties 23.748 Total non\\u002d\\u002dcurrent liabilitie s 4,69,621 Current liabilit ies: Financial liabil~ies (i) Borrowings 58,858 (ii) Lease liabiHttes 3.550 (iii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises 1,296 (b) Total outstanding dues of creditors other than micro enterprises and small enterprises 98,412 (iv) Other financial liabilities 57.530 Other current liabilities 17,823 Provisions 11.809 Total curren t liabilities 2,49,278 TOTAL EQUITY AND LIABILIT IES 18,72,212 \/in ( lakhs\/ As at March 31, 2026 Aud ited 5,62.800 1,35,1 96 59,224 466 3,48,824 2,51,820 81 546 7,915 74,645 20,391 26,405 4,649 35,653 15,28,615 11,428 96,975 66,580 3,480 7,057 3,480 5,479 1,94,479 17,23,094 97,313 9,77,350 10,74,663 10,74,663 2,43,866 53.932 26,857 12.782 68.753 23.547 4,29,737 46,816 3.222 1,260 84.644 57.253 17.356 8.143 2,18,694 17,23,094 s.R. Batllbol & Co. t P, for Identification ~ MAX HEALTHCARE INSTITUTE LIMITED CIN : L72200MH2001 PLC322854 REGISTERE D OFFICE\"},{\"title\":\"Press Release\",\"summary\":\"a press release dated October 30, 2026, titled \\\"Max Healthcare Q2 revenue rises to Rs 3219 Crore registering growth of 20% YoY Q2 PAT stood at Rs 448 Cr growth of 10% YoY\\\".\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 14:48:29\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026144807_PR_EU_Vf.pdf\",\"disclosure_text\":\"October 30, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MAXHEALTH Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543220 Sub.: Press Release and Presentation on Earnings Update Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir \/ Madam, Please find enclosed herewith the press release titled \u201cMax Healthcare Q2 revenue rises to \u20b9 3,219 Cr, registering growth of 20% YoY; Q2 PAT stood at \u20b9 448 Cr, growth of 10% YoY\u201d along with presentation on earnings update for the quarter and half year ended September 30, 2026. This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above (1) Network includes the Company, its subsidiaries, managed hospitals and partner healthcare facilities| (2) Normalized for one-time tax gain of \u20b9 149 Cr | (3) Avg. Revenue per IP Patient is based on Gross IP revenue, excluding chemotherapy, dialysis & radiotherapy | (4) After interest, tax, working capital changes and replacement capex Max Healthcare Q2 revenue rises to \u20b9 3,219 Cr, registering growth of 20% YoY Q2 PAT stood at \u20b9 448 Cr, growth of 10% YoY Key Highlights of Q2 Performance \u2022 Gross Revenue stood at \u20b9 3,219 Cr, a growth of 20% Y oY \u2022 Network(1) PAT stood at \u20b9 448 Cr, compared to \u20b9 406 Cr(2) in Q2 FY26 and \u20b9 357 Cr in Q1 FY27, registering a growth of 10% YoY \u2022 Operational bed capacity at end of Sep\u201926 stood at 5,518, up by 758 beds (+16% YoY) compared to Sep\u201925 \u2022 Bed occupancy for the quarter was at 77%, with Occupied Bed Days (OBDs) up by 13% YoY \u2022 During the quarter over 31 lakh episodes of patient services delivered (OP, IP and day care) across the Network, reflecting a growth of 12% YoY \u2022 Free treatment provided to 55,296 patients in OPD and 1,738 patients in IPD from the economically weaker sections by the Network Hospitals \u2022 ARPP(3) for Q2 FY27 stood at \u20b9 2.31 lakh compared to \u20b9 2.14 lakh in Q2 FY26 and \u20b9 2.30 lakh in Q1 FY27, representing a growth of 8% YoY \u2022 Free Cash from Operations(4) was \u20b9 500 Cr in Q2 FY27 compared with \u20b9 291 Cr in Q2 FY26 and \u20b9 397 Cr in Q1 FY27. Of this, \u20b9 292 Cr was invested in ongoing expansion and \u20b9 195 Cr was disbursed towards dividend for FY \u201926. Further, \u20b9 2 Cr was received from the exercise of ESOPs \u2022 Net Debt at end of Sep \u201826 stood at \u20b9 2,369 Cr compared to \u20b9 2,384 Cr at end of Jun \u201826 \u2022 MSSH, Dwarka has commenced services at new Oncology Block , which consists of Chemotherapy Day Care, Dialysis Centre, nuclear medicine and LINAC facilities \u2022 Consequent to a rights issue by Kalinga Hospital Limited (KHL) in Sep 2026, which owns and operates a 250 beds hospital in Bhubaneswar and secondary purchase of 50,000 shares, the Company\u2019s shareholding in KHL has increased from ~58.28% to ~66.34% \u2022 The Board has approved capital expenditure of \u20b9 415 Cr for addition of 209 brownfield beds across existing hospitals. This includes 85 beds at MSSH, Noida, 60 beds at MSSH, Vaishali and 64 beds at BLK Max Delhi, October 30, 2026: Max Healthcare Institute Ltd . (MHIL, \u2018the Company\u2019), one of the largest private sector healthcare services companies in India, announced its financial and operating results for the second quarter and half year ended September 30, 2026. Network gross revenue was \u20b9 3,219 Cr, reflecting a growth of 20% YoY and 8% QoQ, mainly driven by increase in OBDs. International patient revenue stood at \u20b9 307 Cr, reflecting a growth of 33% YoY and accounting for ~ 10% of the hospital revenue. Max Lab (non -captive pathology vertical) reported a gross revenue of \u20b9 66 Cr during the quarter, recording a growth of 24% YoY and 15% QoQ. Max Lab services are now available across 63+ cities, and it offers a comprehensive range of over 2,700+ tests. Max@Home reported a gross revenue of \u20b9 86 Cr, reflecting a growth of 37% YoY and 10% QoQ, driven by physio, rehab and pathology sample collection service lines. Network PAT stood at \u20b9 448 Cr compared to \u20b9 406 Cr in Q2 FY26 and \u20b9 357 Cr in Q1 FY27, reflecting a growth of 10% YoY on a like to like basis. (1) After interest, tax, working capital changes and replacement capex | (2) After considering term loans, cash credit and put option liability Free cash from operations (1) stood at \u20b9 500 Cr compared to \u20b9 291 Cr in Q2 FY26 and \u20b9 397 Cr in Q1 FY27. Of this, \u20b9 292 Cr was invested in ongoing expansion plans and \u20b9 195 Cr was disbursed towards dividend. Further, \u20b9 2 Cr was received from the exercise of ESOPs Net Debt(2) at end of Sep \u201826 stood at \u20b9 2,369 Cr compared to \u20b9 2,384 Cr at end of Jun \u201826. MSSH Dwarka has commenced services at the Oncology Block. The facility comprises of Chemotherapy Day Care Unit, Dialysis Centre, LINAC, PET-CT and Pathology Lab. The commissioning of Oncology Block will enable the main hospital to reach a total bed capacity of 318 beds in the course of Q3 FY27 Consequent to a rights issue by KHL, which owns and operates a 250 beds hospital in Bhubaneswar and secondary purchase of 50,000 shares , the Company\u2019s shareholding in KHL has increased from ~58.28% to ~66.34% as on September 7, 2026. The Board approved capital expenditure of \u20b9 415 Cr for addition of 209 brownfield beds across existing hospitals to augment capacity. This includes 85 beds at MSSH , Noida and 60 beds at MSSH , Vaishali. At BLK Max, 64 beds will be added along with a Multi-Level Car Parking tower to support the increased patient and visitor footfall. Half year ended September 30, 2026 For the half year ended September 2026, total bed capacity stood at 6,184 beds, an increase of 20% YoY. Network gross revenue stood at \u20b9 6,200 Cr, representing a growth of 18% over the corresponding period last fiscal, mainly driven by increase in OBDs. Network PAT stood at \u20b9 805 Cr, up 7%, compared to \u20b9 750 Cr in corresponding year last fiscal on a like to like basis. Cash from operations for the Network during half year ended Sep \u201826 was \u20b9 897 Cr. Net Debt stood at \u20b9 2,369 Cr. Commenting on Q2 results, Mr. Abhay Soi, Chairman and M anaging Director , Max Healthcare Institute Ltd., said: \u201cWe continue to deliver steady growth as we expand our bed capacity across multiple locations to meet India\u2019s growing need for quality healthcare. Higher occupancy levels across our network hospitals reflect this demand. We are witnessing a faster ramp -up in occupancy of newly added beds, indicating a robust demand and absorption of added capacity. Medical value travel is also witnessing strong growth, driven by the cost competitiveness of healthcare services in India, further strengthening the country\u2019s position as a leading global healthcare destination.\u201d (1) As a percent of net revenue Financial and Operational Highlights (Overall Basis): Particulars (in \u20b9 Cr) Three months ended Growth Half year ended Growth Sep\u201926 Sep\u201925 Jun\u201926 YoY QoQ Sep\u201926 Sep\u201925 YoY Gross Revenue 3,219 2,692 2,982 20% 8% 6,200 5,266 18% Net Revenue 3,055 2,580 2,835 18% 8% 5,890 5,039 17% Operating EBITDA 820 694 704 18% 16% 1,524 1,308 17% Margin %(1) 26.8% 26.9% 24.8% 25.9% 25.9% PAT 448 406(1) 357 10% 26% 805 750(1) 7% Net Debt\/(Cash) 2,369 2,067 2,384 2,369 2,067 (1) normalized for one-time tax gain of \u20b9 149 Cr Clinical Update: \u2022 ~4,978 Liver Transplants, ~6,329 Kidney Transplants & ~2,348 Bone Marrow Transplants performed till date \u2022 At MSSH , Dwarka, a 63-years-old patient from Cambodia with HBV -related cirrhosis, hepatocellular carcinoma and end -stage renal disease successfully underwent a simultaneous living donor liver-kidney transplant \u2022 MSSH, Dehradun successfully performed its first liver transplant in a 46 years old patient, marking a significant milestone in establishing advanced transplant services in the region Research and Academics: \u2022 Published 123 articles in high impact journals during Q2 FY27 \u2022 130 clinical trials and 25 grant studies are ongoing \u2022 900+ clinical research projects completed till date, ~155 ongoing \u2022 610+ MBBS doctors in DNB programmes across 40+ specialities \u2022 1,000+ new students enrolled in the Online Courses for various e-learning courses About Max Healthcare: Max Healthcare Institute Limited (Max Healthcare) is one of India\u2019s largest healthcare organizations. It is committed to the highest standards of clinical excellence and patient care, supported by latest technology and cutting-edge research. Max Healthcare operates 21 healthcare facilities (~6,200 beds) with a significant presence in North India. The network consists of all the hospitals and medical centres owned and operated by the Company and its subsidiaries, partner healthcare facilities and managed healthcare facilities, which includes state -of-the-art tertiary and quaternary care hospitals located at Saket (3 hospitals), Patparganj, Vaishali, Rajendra Place, Dwarka, Noida and Shalimar Bagh in Delhi NCR and one each in Lucknow, Mumbai, Nagpur, Mohali, Bathinda , Dehradun, and Bhubaneswar, secondary care hospital in Gurgaon and medical centres at Noida, Lajpat Nagar and Panchsheel Park in Delhi NCR, and one in Mohali, Punjab. The hospitals in Mohali and Bathinda are under PPP arrangement with the Government of Punjab. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively. Max@Home offers health and wellness services at home while Max Lab provides diagnostic services to patients outside the network. Max Healthcare Institute Ltd. (NSE Symbol: MAXHEALTH, BSE scrip code: 543220) For more information, visit www.maxhealthcare.in or please contact: Shruti Verma at shruti.verma@maxhealthcare.com \/ +919811566975 Safe Harbour Disclaimer This release contains certain \u201cforward looking statements\u201d including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Max Healthcare Institute Limited\u2019s (\u201cMHIL\u201d) future business d evelopments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market conditions, macro -economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressur es, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors beyond the control of MHIL, such as Covid-19, that could affect our business and financial performance. MH IL undertakes no obligation to publicly revise any forward- looking statements to reflect future \/ likely events or circumstances. In addition, this release is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The financial information outlined in this press release is unaudited, base d on management accounts and has not been subjected to any limited review by any auditor or chartered accountant. This information, includes those relating to Partner Healthcare Facilities. However, the same have neither been verified by the Company nor by its Subsidiaries. Accordingly, limited reliance should be placed on such financial information. Further, such financial information contained herein should not be viewed as being indicative of MHIL\u2019s financial performance going forward. MHIL may alter, modify or otherwise change in any manner the content of this release, without obligation to notify any person of such change or changes. This release should not be copied or disseminated in any manner. Earnings update \u2013 Q2 & H1 FY27 October 30, 2026 Disclaimer This presentation contains certain \u201cforward looking statements\u201d including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Max Healthcare Institute Limited\u2019s (\u201cMHIL\u201d \/ \u201cMHC\u201d) future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market conditions, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory developments, and other key factors beyond the control of MHIL, such as lockdowns etc. that could adversely affect our business and financial performance. MHIL undertakes no obligation to publicly revise any forward looking statements to reflect future \/ likely events or circumstances. In addition, this presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The financial information outlined in this presentation is different from that of the consolidated financials of MHIL since the financial information of the Partner Healthcare Facilities (PHFs) is included in this presentation and hence might not meet statutory, regulatory or other audit or similar stipulated requirements. Further, the financial information contained in this presentation is based on the unaudited financials of the Company, its subsidiaries, Managed Healthcare Facilities along with the unaudited financial information (prepared under IGAAP) of the PHFs as received from such partners and updated for intra-network eliminations and IND AS related adjustments. The financial information relating to PHFs post IND AS adjustments, have neither been verified by the Company nor by its Subsidiaries or its auditors. Accordingly, to that extent, limited reliance should be placed on the financial information of such PHFs included in this presentation. MHIL may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. This presentation should not be copied or disseminated in any manner. The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or recommendation or solicitation of an offer to subscribe to securities for or invitation to purchase any securities of MHIL. This presentation should not, nor should anything contained in it, form the basis of, or be relied upon in any connection with any contract or commitment, whatsoever. 2 Notes to Network Consolidated Financials 1. Max Healthcare Institute Limited (\u201cMHIL\u201d), its subsidiaries and deemed separate entities (i.e. silos for Managed Healthcare Facilities) constitute MHIL Group under IND AS 110. MHIL Group also has long term contracts with certain societies, who own and operate hospitals and act in concert with other Max Hospitals to provide high end medical care to the communities. MHIL Group carries significant financial exposure to these Societies, who are treated as Partner Healthcare Facilities (\u201cPHF\u201d) and form part of Network Hospitals. Given the financial exposure, operating model and to present correct performance indicators, it is considered appropriate by MHIL management to also disclose the financial performance of the Network Hospitals as a whole, by way of a certified memorandum consolidation of financial results of operations of MHIL, its subsidiaries, managed healthcare facilities and PHFs (all these entities combined together are referred as \u201cNetwork\u201d). 2. The financial information contained in this presentation is thus different from that of the MHIL Group since the financials of Partner Healthcare Facilities (PHFs) are also included. The information is drawn up based on the management consolidation of the reviewed financials of the Company, its subsidiaries, Managed Healthcare Facilities and those of the PHFs (prepared under IGAAP), duly adjusted for intra-network eliminations and IND AS related adjustments. Such consolidated financial information is then certified by an independent firm of chartered accountants. 3. Healthcare undertaking of Radiant Life Care Private Limited (\u201cRadiant\u201d) and residual business of erstwhile Max India Limited merged into Max Healthcare Institute Limited (\u201cMHIL\u201d or \u201cthe Company\u201d) through an NCLT approved Composite Scheme of Amalgamation and Arrangement on June 1, 2020. The Group, while accounting for the Business Combination under reverse merger carried out a fair valuation exercise, leading to an increase of \u20b9 3,662 Cr in carrying value of tangible and intangible assets, including \u20b9 252 Cr attributable to PHF, with a corresponding increase in Equity and Liabilities. This represented a notional increase in capital employed, without any investment in\/by the Company. Subsequently, the Company acquired additional subsidiaries (including a step-down subsidiary) from time to time. These acquisitions were also accounted for as Business Combinations, with Purchase Price Allocation exercises undertaken for each acquisition. As a result, the carrying value of tangible and intangible assets has further increased by \u20b9 385 crore over and above the investment value recognized for these acquisitions. 4. The Profit and Loss statement in this Earnings Update is prepared after line by line consolidation of the financials of MHIL, its subsidiaries, deemed separate entities\/silos and PHFs, after eliminating intra Network\"},{\"title\":\"Outcome of Board Meeting\",\"summary\":\"Max Healthcare Institute Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 14:44:42\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026144248_Outcome_BM.pdf\",\"disclosure_text\":\"October 30, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MAXHEALTH Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543220 Sub.: Outcome of Board Meeting Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir \/ Madam, In continuation to our earlier intimation dated October 23, 2026, we wish to inform that the board of directors (\u201cBoard\u201d) of the Company at their meeting held today i.e. October 30, 2026, inter-alia, transacted following businesses: Financial Results Approved the unaudited standalone & consolidated financial results (\u201cFinancial Results\u201d) of the Company for the quarter and half year ended September 30, 2026, based on the recommendation of Audit Committee. Financial Results together with unmodified limited review reports issued by M\/s. S.R. Batliboi & Co. LLP, Chartered Accountants, Statutory Auditors of the Company are enclosed as Annexure - I. Capital expenditure for expansion of Max Super Speciality Hospital, Sector-128, Noida Approved capital expenditure of ~\u20b993 Crore towards the redevelopment and clinical capacity enhancement programme at Max Super Speciality Hospital, Sector -128, Noida (\u201cMSSH Noida\u201d). MSSH Noida is run and operated by Crosslay Remedies Limited (formerly known as \u2018Jaypee Healthcare Limited\u2019) , a wholly -owned subsidiary of the Company (\u201cCrosslay\u201d). Details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u201c SEBI Listing Regulations\u201d) are enclosed as Annexure - II. Capital expenditure for expansion of Max Super Speciality Hospital, Vaishali Approved capital expenditure of ~\u20b997 Crore towards the construction of additional floors at over the existing tower at Max Super Speciality Hospital, Vaishali (\u201cMSSH Vaishali\u201d). MSSH Vaishali is run and operated by Crosslay. Details as required under the SEBI Listing Regulations are enclosed as Annexure - III. Appointment of Senior Management Personnel Approved the appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs , identified as Senior Management Personnel with effect from November 1, 2026 , based on the recommendation of Nomination and Remuneration Committee. Details as required under the SEBI Listing Regulations are enclosed as Annexure - IV. Update on Construction of ~525 bedded hospital at Sector - 56, Gurugram In continuation of our earlier intimation dated May 22, 2024, approved the revision of the project cost to ~\u20b91,143 Crore and the timeline for completion of the proposed ~525 bedded hospital at Sector - 56, Gurugram to April 2027. The revision in project cost is primarily attributable to changes in fa\u00e7ade specifications, additional construction requirements, development of the atrium and enhanced interior fit -outs. All other aspects of the project, other than the revised project cost and completion timeline, remain unchanged. The Board meeting commenced at 12.50 pm (IST) and concluded at 2.35 pm (IST). This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above S.R. BArL1B01 & Co. LLP Chartered Accountants 67. Institutional Area Sector 44, Gurugram - 122 003 Haryana, India Tel : +91 124 681 6000 Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Max Healthcare Institute Limited 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Resu lts of Max Healthcare Institute Limited {the \\\"Holding Company\\\") , its subsidiarie s and its deemed separate ent ities, that is 'Silos' over which the Holding Company has control (the Holding Company , its subsidiarie s and its deemed separate entities that is 'Si los\\\", together referred to as \\\"the Group \\\") for the quarter ended September 30, 2026 and year to date from April I, 2026 to September 30, 2026 (the \\\" Statement\\\") attached herewith , being submitted by the Holding Company pursua nt to the requirement s of Regu lation 33 of the SEB I (L isting Obligat ions and Disclosure Requirements) Regulations , 20 15, as amended (the \\\"List ing Regulations \\\"). 2. The Holding Compan y's Management is responsib le for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Account ing Standard 34, (Ind AS 34) \\\"Interim Financial Reporting \\\" prescribed under Sect ion 133 of the Companies Act, 2013 as amended , read with relevant rules issued thereunder and other accou nting principles genera lly accepted in India and in compliance with Regulation 33 of the Listing Regulation s. The Statement has been approved by the Holdin g Company's Board of Direct ors. Our responsibi lity is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 24 10, \\\"Review of Interim Financial Information Performed by the Independent Auditor of the Entity \\\" issued by the Institute of Chartered Accountants of India. This standa rd requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of materia l misstatement. A review of interim financial information cons ists of making inquiries , primar ily of persons respons ible for financial and accou nting matters , and app lying analytical and other review procedures. A review is substantia lly less in scope than an audit conducted in accorda nce with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly , we do not express an audit opin ion. We also performed procedure s in accordance with the Circular No. CIR\/CFD \/CMD 1\/44\/20 19 dated March 29, 20 19, issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regu lations, to the extent applicable. 4. The Statement includes the resu lts of the following entit ies as mentioned in Annexure I. 5. Based on our review conducted and procedures performed as stated in paragrap h 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompany ing Statement , prepared in accordance with recognition and measurement principles laid down in the aforesa id Indian Account ing Standards ('Ind AS') specifie d under Section 133 of the Comp;mies Act, 2013 , as amended , read with relevant rules issued thereunder and other accounting principles generally accepted in India , has not disclosed the informat ion required to be disclosed in terms of the Listing Regulations , including the manner in which it is to be disclosed , or that it contains any material misstate ment. 6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of four subsidiaries , whose unaudited interim financial results include total assets of Rs. 33,690 Lakhs as on September 30, 2026, tota l revenues of Rs. 3,666 Lakhs and Rs. 5,547 Lakhs , total net profit after tax of Rs. 20 Lakhs and Rs. 81 Lakhs, total comp rehensive incom e of Rs. 5 Lakhs and Rs. 68 Lakhs , for the quarter ended September 30, 2026 , and the period ended on that date respectively , and net cash inflow of Rs. 8,777 Lakhs for the period from Apr il O I, 2026 , to September 30, 2026, as considered in the Statement which have been reviewed by their respective indepe ndent auditors. S.R. Batlibol g Co LLP, a Limited Llablllty Partnership with LLP Identity No. AAB\u20224 294 Rcgd Office\u00b7 22. Cam,,c S1n:-c1. Block \u00b7e\u00b7. Jrd Floor. Kolk.11a-700 016 S.R. BArL1B01 & Co. LLP Chartered Accountants The independent auditor ' s reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Stateme nt, in so far as it relates to the amount s and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedure s perfo rmed by us as stated in paragraph 3 above. 7. The accompany ing Statement include s unaud ited interim financ ial results and other unaudit ed financia l information in respect of two subsidiarie s, whose interim financia l results and other financial inform ation reflect total assets of Rs. 936 Lakh s as on September 30, 2026 , total revenues of Rs. nil and Rs. nil, total net (loss) after tax of Rs. (532) Lakh s and Rs. (862) Lakhs, total comprehensive (loss) of Rs. (533) Lakhs and Rs. (864) Lakh s, for the quarter ended Septemb er 30, 2026 , and period ended on that date respectively , and net cash outflo ws of Rs. ( 140) Lakhs for the period from April 01 , 2026 , to Sept ember 30, 2026. The unaudited interim financial results and other unaudit ed financ ial inform ation of these subsidiaries have not been rev iewed by thei r auditor(s) and hav e been approved and furnished to us by the Management and our conclusion on the Statement , in so far as it relate s to the affair s of these subsidiar ies, is based solely on such unaudited interim financia l results and other unaudited financial informat ion. Accordin g to the information and explanations given to us by the Man agement , these inter im financia l resu lts are not materia l to the Group . Our conc lusion on the Statement in respect of matt ers stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the finan cial results certified by the Management. For S.R. Batliboi & Co. LLP Chartered Accountants ICAI Finn regi stration numb er: 30 I 003E\/E3 0000 5 \u00bd:cl\\u002d\\u002d per San jay Vij Partner Memb ership No.: 095 169 UDIN: l-1, 0'15 \\\\1,q Wy\\\\\/0 L-Jq511 Place : New Delhi Date: October 30, 2026 S.R. BATLIBOI & Co. LLP Chartered Accountants Annexure 1 to our report dated October 30, 2026, on the consol idated financia l results of Max Healt hcare Institute Limited for the qua rter ended September 30, 2026, and year to date from April 01, 2026 to Septem ber 30, 2026 List of subsidiaries \/ step down subsidia ries\/ silos S. No. Com pany Name Relationship 1 ALPS Hospital Limited (Formerly known as Max Hospitals Subs idiary Company and Allied Services Limited) 2 Hometrail Buildtech Private Limited Subsidiary Company 3 Crosslay Remedies Limited (Formerl y known as Jaypee Subsidiary Company Healthcare Limited) 4 Max Lab Limited Subsidiary Company 5 Eqova Healthc are Private Limited Subsidiary Company 6 Alexis Multi Specia lity Private Limited Subs idiary Company 7 Starl it Medical Centre Private Limited Step-down Subsidiary Company 8 Max Healthc are FZ LLC Subsidiary Company 9 MHC Global Healthcare (N igeria) Limited (Liquidat ed w.e.f. Subsidiary Company October 28, 2026) 10 Max Healthcare Foundatio n Subsidiary Company I I Kalinga Hospita l Limited (w.e .f. May 18, 2026) Subsidiary Company 12 Yerawada Propertie s Private Limited (w.e.f. June 30, 2026) Subsid iary Company 13 Operations of Dr. B.L. Kapur Memorial Hospital (A unit of Silo Lahore Hospital Society) 14 Operation s of Dr. Balabhai Nanavati Hospital (A unit of Silo Balabhai Nanavat i Hospital) 15 Operation s of Max Super Speciali ty Hospital, Dwarka (A unit Silo of Muthoot Hospitals Private Lim ited) SI. No. 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. MAX HEALTHCARE INSTITUTE LIMITED CIN : L72200M H2001PLC322854 REGISTERED OFFICE: 401, 4th Floor , Man Excellenza, S. V. Road , Vile Parle (West), Mumbai-400056, Maharashtra Website : www.maxhealthcare.in . Email : investors@maxhealthcare .com. Phone : +91- 22 2610 0461 \/62 STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF-YEAR ENDED SEPTEMBER 30, 2026 fin t lakhs excent ner eauitv share data) Pani culars Quarter ended September 30, June 30, 2026 2026 Unaudited Unaudit ed Income Revenue from operations 2.56.921 2.36.617 Other income 4.090 4,052 Total Income 2,61,011 2.40.669 Expenses Purchase of drugs. consumables and implants 52.194 52.116 Change in inventories of drugs. consumables and implants (663) (778) Employee benefits expense 39.931 38.818 Professional and consultancy fee 56.413 52.343 Finance costs 7.384 7.100 Depreciation and amortization expense 13.763 13.166 Other expenses 37.897 34.273 Total expenses 2,06,919 1 97,038 Profit before exceptional items and tax for the period\/yea r (1-2) 54,092 43,631 Exceptiona l items (refer note 5) Profit before tax for the oeriod\/vear 13-41 54,092 43,631 Tax expense (refer note 10) Current tax 9.531 8,246 Deferred tax charge\/(credit) 3,116 3.089 Total tax expense 12,647 11,335 Profit for the oeriod\/vear 15-61 41.445 32,296 Other comprehensive income Items that will not be reclassified to profit or loss Remeasurement of defined benefit plans 35 8 Income tax effect on above (6) (6) ltoms that will bo reclassified to profit or loss Fair value changes on derivalives designated as cash flow hedge 1.018 (644) Income tax effect on above (256) 162 Exchange differences on translation of foreign operation (1) (1) Other comprehensive income\/floss I 790 (481 Total comprehensive income for the oeriod\/vea r 17+8\\\\ 42.235 31,815 Profit\/(l oss) attribu table to: 41,445 32,296 Owners of the company 41.494 32.249 Non-controlling interests (49) 47 Other Comp rehensive income\/(loss) attribu table to: 790 (481) Owners of the company 796 (482) Non\u2022controlling interests (6) 1 Total Comprehensive incomef(loss) attributab le to: 42,235 31,815 Owners of the company 42.290 31.767 Non-controlling interests (55) 48 Paid-up equity share capita l 97,331 97,324 (Face value oft 10 per share) Reserves (other equity) Earnings per equity share (EPS) Not annualised Not annualised Basic-m 4.26 3.32 Diluted - (t) 4.24 3.30 Consolidated September 30, 2025 Unaudi ted 2.13.547 3.290 216,837 46.515 (26) 33.832 45.273 5,392 10.810 30.438 1 72,234 44,603 44,603 1.029 (5.556) 14,5271 49. 130 20 (1) (15) 4 49,134 49,130 49.130 4 4 49.134 49.134 97,224 Not annualised 5.05 5.02 Half-year ended September 30, September 30, 2026 2025 Unaudited Unaudited 4.93.538 4.16.304 8.142 6.941 5,01 680 423,245 1.04.310 91.897 (1.441) (884) 78.749 67.639 1.08.756 87.912 14.484 10.877 26.929 21.224 72.170 59.934 4,03,957 338,599 97,723 84,646 97 723 84.646 17.777 10.673 6.205 (5.954) 23.982 4,719 73 741 79,927 43 (326) (12) 65 374 (94) (2) (16) 309 1277 74,050 79.650 73,741 79,927 73.743 79.927 (2) 309 (277) 314 (277) (5) 74,050 79,650 74.057 79.650 (7) 97,331 97,224 Not annualised Not annualised 7.58 8.22 7.54 8.17 S.R. Ballibol & Co.i LP, for Identification~ Year ended March 31, 2026 Audited 8,37.345 16.262 8,53,607 1.79.875 (873) 1.35.712 1.79.401 23.510 44.653 1.18.947 6,81,225 1,72,382 4,824 1 67,558 21.131 2.186 23,317 1,44.241 (181) (3) 26 (158 1.44.083 1,44.241 1.44.241 (158) (158) - 1,44,083 1.44.083 97,313 9,77,350 Annualised 14.83 14.76 MAX HEALTHCARE INSTITUTE LIMITED CIN : L72200MH2001 PLC322854 REGISTERED OFFICE : 401, 4th Floor, Man Excellenza , S. V. Road, Vile Parle (West) , Mumbai-400056 , Maharashtra Website: www.m axhealthcare.in. Email: investors@maxhea lthcare.com. Phone: +91-22 2610 0461\/62 UNAUDITED CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2026 As at Part icul ars September 30, 2026 Unaudited ASSETS Non-current assets: Property, plant and equipment 6.05,366 Right-of-use assets 1.71,011 Capital worl<-in-prngress 80,451 Investment property 466 Goodwill 3,68,920 Other intangible assets 2,49,928 Intangible assets under developme nt 945 Financial assets ( i) Investments 546 (ii) Trade receivables 7,348 (iii) Loans 83.996 (iv) Other financial assets 23,315 Income tax assets (net) 31,522 Deferred tax assels 3,198 Other non-current assets 35,574 Total non.current assets 16,62,586 Current assets : Inventories 13,181 Financial assets (i) Trade receivables 1,24,336 (ii) Cash and cash equivalents 55.671 (iii) Bank balances other than (ii) above 1,425 (iv) Loans 987 (v) Other financial assets 6,988 Income lax assets (net) 451 Other current assets 6.587 Total current assets 2,09,626 TOTAL ASSETS 18,72,212 EQUITY AND LIABILITIES EQUITY Equijy share capital 97,331 Other equity 10,35,872 Equity attributable to owners of the Compa ny 11,33,203 Non-controlling interests 20,110 Total equity 11,53,313 LIABILITIES Non-current llabiliti es: Financial liabiltties (i) Borrowings 2,62,098 (ii) Lease liabilities 54,997 (iii) Other financial liabilities 32,277 Provisions 13.916 Deferred tax liabilities 82.585 Other non\\u002d\\u002dcurrent liabihties 23.748 Total non\\u002d\\u002dcurrent liabilitie s 4,69,621 Current liabilit ies: Financial liabil~ies (i) Borrowings 58,858 (ii) Lease liabiHttes 3.550 (iii) Trade payables (a) Total outstanding dues of micro enterprises and small enterprises 1,296 (b) Total outstanding dues of creditors other than micro enterprises and small enterprises 98,412 (iv) Other financial liabilities 57.530 Other current liabilities 17,823 Provisions 11.809 Total curren t liabilities 2,49,278 TOTAL EQUITY AND LIABILIT IES 18,72,212 \/in ( lakhs\/ As at March 31, 2026 Aud ited 5,62.800 1,35,1 96 59,224 466 3,48,824 2,51,820 81 546 7,915 74,645 20,391 26,405 4,649 35,653 15,28,615 11,428 96,975 66,580 3,480 7,057 3,480 5,479 1,94,479 17,23,094 97,313 9,77,350 10,74,663 10,74,663 2,43,866 53.932 26,857 12.782 68.753 23.547 4,29,737 46,816 3.222 1,260 84.644 57.253 17.356 8.143 2,18,694 17,23,094 s.R. Batllbol & Co. t P, for Identification ~ MAX HEALTHCARE INSTITUTE LIMITED CIN : L72200MH2001 PLC322854 REGISTERE D OFFICE\"},{\"title\":\"Allotment of Securities\",\"summary\":\"allotment of Equity Shares under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 11:01:17\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026110106_SE_Intimation_Allotment_of_Equity_Shares.pdf\",\"disclosure_text\":\"October 30, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MAXHEALTH Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543220 Sub.: Allotment of Equity Shares under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 Dear Sir \/ Madam, We wish to inform that Nomination & Remuneration Committee (\u201cNRC\u201d) of the Company in its meeting held today i.e. October 30, 2026, has approved the allotment of 16,803 equity shares having face value of \u20b910 each, fully paid-up, to eligible employees, consequent to the exercise of vested stock options in accordance with Max Healthcare Institute Limited - Employee Stock Option Scheme 2022. Consequent to the above allotment, the paid-up equity share capital of the Company stands increased as under: Particulars Pre-allotment Post-allotment No. of Equity Shares 97,33,10,251 97,33,27,054 Face Value (\u20b9) 10 10 Paid-up Equity Capital (\u20b9) 973,31,02,510 973,32,70,540 In terms of regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, the requisite details of equity shares allotted as above are enclosed as Annexure. The NRC meeting commenced at 10.31 am (IST) and concluded at 10.48 am (IST). This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above Annexure Details with respect to allotment of Equity Shares under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 S. No. Particulars Details 1. Company name and address of Registered Office Max Healthcare Institute Limited 401, 4th Floor, Man Excellenza, S. V. Road, Vile Parle (West), Mumbai - 400 056, Maharashtra 2. Name of the recognized Stock Exchanges on which the company\u2019s shares are listed BSE Limited (\u201cBSE\u201d) National Stock Exchange of India Limited (\u201cNSE\u201d) 3. Filing date of the statement referred in regulation 10(b) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, with the recognized Stock Exchange September 29, 2022 4. Filing Number, if any BSE: DCS\/IPO\/MJ\/ESOP-IP\/2511\/2022-23 NSE: NSE\/LIST\/32765 5. Title of the Scheme pursuant to which shares are issued, if any Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 6. Kind of security to be listed Equity Shares 7. Par value of the shares \u20b910 per equity share 8. Date of allotment of Shares October 30, 2026 9. Number of shares allotted 16,803 equity shares 10. Share Certificate No., if applicable Not applicable, as the equity shares issued in dematerialized form 11. Distinctive number of the share, if applicable 97,33,10,252 to 97,33,27,054 (Both inclusive) 12. ISIN Number of the shares if issued in Demat INE027H01010 13. Exercise price per share \u20b9350 per equity share 14. Premium per share \u20b9340 per equity share 15. Total issued shares after this issue 97,33,27,054 equity shares 16. Total issued share capital after this issue \u20b9973,32,70,540 17. Details of any lock-in on the shares Not Applicable 18. Date of expiry of lock-in Not Applicable 19. Whether shares are identical in all respects to existing shares? If not, when will they become identical? Yes, Equity shares are identical in all respect to existing equity shares 20. Details of listing fees, if payable Not applicable Note: The aforesaid allotment of equity shares is not material in nature for the Company in terms of regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.\"},{\"title\":\"ESOP\/ESOS\/ESPS\",\"summary\":\"grant of options under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022\",\"source\":\"NSE\",\"published\":\"30-Oct-2026 10:57:40\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026105713_SE_Intimation_Grant_of_ESOPs.pdf\",\"disclosure_text\":\"October 30, 2026 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 Symbol: MAXHEALTH Listing Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Scrip Code: 543220 Sub.: Grant of options under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 Ref.: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir \/ Madam, We wish to inform that Nomination and Remuneration Committee (\u201cNRC\u201d) of the Company in its meeting held today i.e. October 30, 2026 , has approved the grant of 95,000 stock options to eligible employee s under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022. Details pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as Annexure. The NRC meeting commenced at 10.31 am (IST) and concluded at 10.48 am (IST). This disclosure will also be hosted on Company's website viz. www.maxhealthcare.in. Kindly take the same on record. Thanking you Yours truly, For Max Healthcare Institute Limited Dhiraj Aroraa EVP - Company Secretary and Compliance Officer Encl.: As above Annexure Details with respect to Grant of Stock Options S. No. Particulars Details 1. Brief details of options granted Grant of 95,000 stock options under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022 (\u201cMHIL ESOP - 2022\u201d) to eligible employees. 2. Whether the scheme is in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 (if applicable) Yes 3. Total number of shares covered by these options 95,000 equity shares as each stock option convertible into one fully paid-up equity share having face value of \u20b910 each. 4. Pricing formula\/ Exercise Price\/ Grant Price \u20b9800 per stock option 5. Options vested \/ vesting schedule Subject to fulfillment of pre-vesting conditions, not earlier than 1 (one) and not later than 5 (five) years from the date of grant of options, as per the terms and conditions determined by the Nomination and Remuneration Committee of the Company. 6. Time within which option may be exercised 3 (three) years from the respective date of vesting of stock options. 7. Brief details of significant terms Stock options granted are governed under the MHIL ESOP - 2022, which is administered and implemented by the Nomination and Remuneration Committee. 8. Options exercised Not applicable 9. Money realized by exercise of options 10. The total number of shares arising as a result of exercise of option 11. Options lapsed 12. Variation of terms of options 13. Subsequent changes or cancellation or exercise of such options 14. Diluted earnings per share pursuant to issue of equity shares on exercise of options\"}],\"recent_news\":[{\"summary\":\"Presentation on Earnings Update for the quarter and half year ended September 30, 2026.\",\"category\":\"General Updates\",\"date\":\"30-Oct-2026 14:57:07\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026145653_PR_EU_Vf.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"a press release dated October 30, 2026, titled \\\"Max Healthcare Q2 revenue rises to Rs 3219 Crore registering growth of 20% YoY Q2 PAT stood at Rs 448 Cr growth of 10% YoY\\\".\",\"category\":\"Press Release\",\"date\":\"30-Oct-2026 14:48:29\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026144807_PR_EU_Vf.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Max Healthcare Institute Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"30-Oct-2026 14:44:42\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026144248_Outcome_BM.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"appointment of Dr. Dharmender Kumar as Director & Chief - Public Affairs, identified as Senior Management Personnel effective November 1, 2026.\",\"category\":\"Change in Management\",\"date\":\"30-Oct-2026 14:54:35\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/MAXHEALTH_30102026145418_Outcome_BM.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":5}],\"shareholding_snapshot\":{\"promoter_pct\":23.71,\"public_pct\":76.29,\"fii_pct\":40.52,\"dii_pct\":31.0,\"mf_pct\":19.25,\"institutional_pct\":71.52,\"noninst_pct\":4.76,\"mf_scheme_count\":40,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"Hdfc Mutual Fund through various schemes\",\"shares\":31748955,\"pct\":3.26},{\"name\":\"Invesco Mutual Fund through various schemes\",\"shares\":27893560,\"pct\":2.87},{\"name\":\"SBI Mutual Fund through various schemes\",\"shares\":25174516,\"pct\":2.59},{\"name\":\"ICICI Prudential Mutual Fund through various schemes\",\"shares\":17846455,\"pct\":1.83},{\"name\":\"Nippon India Mutual Fund through various schemes\",\"shares\":14995887,\"pct\":1.54}],\"period\":\"30-SEP-2026\",\"submission_date\":\"16-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1740060_16102026044443_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":23.71,\"previous_fii_pct\":41.78,\"previous_dii_pct\":29.96,\"previous_mf_pct\":18.68,\"previous_institutional_pct\":71.74,\"previous_mf_scheme_count\":42,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Max Healthcare Ins share price rose 1.04% to \u20b9860.00 today. See why MAXHEALTH is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":9996,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Max Healthcare Ins Share Price Today: Why MAXHEALTH Is Rising 1.04% | 30 October 2026","_witty_meta_description":"Max Healthcare Ins share price rose 1.04% to \u20b9860.00 today. See why MAXHEALTH is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Max Healthcare Ins share price today","_witty_reason_label":"Earnings release context and sector-aligned participation","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[31],"class_list":["post-9997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-maxhealth"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=9997"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9997\/revisions"}],"predecessor-version":[{"id":9998,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/9997\/revisions\/9998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/9996"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=9997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=9997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=9997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}